GenePool from Station X provides a genome management platform that generates custom reports from cell-free DNA sequencing for clinicians evaluating and monitoring patient tumors 

San Francisco, CA – December 1, 2015.  

Station X, Inc., a leading developer of cloud-based genome management systems for research and precision medicine applications, today announced that Circulogene Theranostics will use its GenePool® platform to analyze and interpret data generated from their cell-free DNA (cfDNA) sequencing-based liquid biopsy services. Circulogene’s proprietary technology is capable of detecting nearly 3,000 cancer mutations on 50 well-established cancer-associated genes and can provide information on current FDA-approved and NCCN/ASCO-endorsed treatment options for the tumor DNA mutations identified.

“Circulogene’s liquid biopsy tumor DNA sequencing is the only test available that combines finger-stick volumes of blood and the most advanced next-generation sequencing to monitor tumor mutant DNA within well-characterized, well-documented cancer-associated genes,” said Circulogene CEO Mike Mullen. “Station X has been instrumental in helping us build our genomic data analysis and reporting workflow. GenePool was the only solution with the flexibility and power to quickly analyze our unique sequencing data and generate reports that aid our clinician customers in planning, implementing and monitoring a patient’s treatment process.”

GenePool from Station X is a secure software-as-a-service enterprise genome management system that allows organizations to access, integrate, distribute and manage their clinical genomic information more efficiently and effectively. GenePool is pre-loaded with standard clinical reporting capabilities for incidental findings and tumor profiling, but its flexibility means organizations like Circulogene can customize GenePool for use with their proprietary gene or variant testing panels and annotations. GenePool also provides a convenient and dynamic way to securely store patient data for updated reporting, ongoing monitoring and for investigating the aggregated information. 

“Leading clinical diagnostic laboratories are adopting GenePool based on its flexible design, demonstrated scalability, and speed in performing deep comparative analyses and generating medically relevant insights,” said Richard Goold, Chief Executive Officer and Co-Founder of Station X. “Our work with Circulogene is an excellent example of how GenePool allows diagnostic laboratories to focus on test innovation and support their customers by leveraging our expertise in genome management and interpretation. We are very proud of our work with Circulogene and are confident that the insights they deliver will help establish liquid biopsies as a new gold standard in cancer care.”

Through GenePool, Circulogene can analyze data across multiple dimensions and develop custom reports supported by rich and ever-growing content libraries such as The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia, ClinVar, COSMIC, dbSNP, FDA Pharmacogenomics Biomarkers, PharmaADME, and many others. Configurable workflows and annotations are supported by interactive visualization tools and a robust Genome Browser. Through a flexible API, GenePool integrates with existing LIMS systems and leading third-party data storage and management platforms including Amazon Web Services, DNAnexus, Google Cloud Platform, Illumina BaseSpace, Microsoft Azure and Seven Bridges Genomics, among others. 

GenePool is available as a web-based service directly from Station X. For more information, please visit

See how Circulogene Theranostics is using GenePool to customize its reporting workflows: Case Study

About Station X
Station X helps life science and healthcare organizations solve integration, collaboration, analysis, visualization, and reporting challenges associated with patient-derived genomics data. The company’s GenePool solution is available as a platform-as-a-service that provides customers with a rich set of built-in functionality alongside seamless integrations with a growing ecosystem of cloud-based storage, compute, and data processing technologies. Armed with GenePool, customers in translational research, biopharmaceutical, and clinical testing environments are maximizing value from their genomics information with an efficient and effective software infrastructure. Station X was founded by experts in commercial bioinformatics technology, who bring decades of collective expertise to support the company’s global customers. For more information, please visit

About Circulogene Theranostics
Headquartered in Birmingham, Ala., Circulogene Theranostics is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the first droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients. For more information, visit or call 205-278-1600.

Media Contact
Colin Sanford

Source: Business Wire